A Phase 1/2 Study of Edasalonexent (CAT-1004) in Pediatric Patients With Duchenne Muscular Dystrophy

Trial Profile

A Phase 1/2 Study of Edasalonexent (CAT-1004) in Pediatric Patients With Duchenne Muscular Dystrophy

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs Edasalonexent (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MoveDMD
  • Sponsors Catabasis Pharmaceuticals
  • Most Recent Events

    • 28 Nov 2017 Planned End Date changed from 1 Mar 2018 to 1 Feb 2019.
    • 04 Oct 2017 According to a Catabasis Pharmaceuticals media release, additional data from this trial is expected to presented in 2018.
    • 04 Oct 2017 According to a Catabasis Pharmaceuticals media release, results from the open-label extension of this trial following 24 and 36 weeks of edasalonexent treatment were presented at the 22nd International Congress of the World Muscle Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top